Protein kinase inhibitors: Induction of apoptosis and drug-resistance modulation in neoplastic cell lines. Minireview

Neoplasma

Volumn 43, Issue 1, 1996, Pages 3-9

  Chorvath B ^a   Sedlak J ^a  

^a Cancer Research Institute   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 7 HYDROXYSTAUROSPORINE; ACRIDINE ORANGE; CALPHOSTIN C; CARDIOTOXIN; CHELERYTHRINE; ERBSTATIN; GENISTEIN; GOSSYPOL; HERBIMYCIN A; K 252A; MIDOSTAURIN; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; PROTEIN KINASE INHIBITOR; STAUROSPORINE; TAMOXIFEN;

ANIMAL CELL; APOPTOSIS; DRUG RESISTANCE; HUMAN; HUMAN CELL; NONHUMAN; REVIEW; TUMOR CELL LINE;

EID: 0029927545     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (71)

1. AKINAGA, S., NOMURA, K., GOMI, K., OKABE, M.: Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32, 1993, 183-189.
2. BERGAMASCHI, G., ROSTI, V., DANOVA, M., PONCHIO, L., LUCOTTI, C., CAZZOLA, M.: Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines. Leukemia, 7, 1993, 2012-2018.
3. BEYAERT, R., VANHAESBROEK, B., HEYNINCK, K., BOONE, E., DEVALCK, D., SCHULTZE-OSTHOFF, K., HAEGEMAM, G., VAN ROY, F., FIERS, W.: Sensitization of tumor cells to tumor necrosis factor action by protein kinase inhibitor staurosporine. Cancer Res., 53, 1993, 2623-2630.
4. BONNEFOY-BÉRARD, N., GENESTIER, L., FLACHER, N., REVILLARD, J.P.: The phosphoprotein phosphatase calcineurin controls calcium-dependent apoptosis in B cell lines. Eur. J. Immunol., 24, 1994, 325-329.
5. BORREGO, F., LOPEZ-BELTRAN, A., PENA, J., SOLANA, R.: Down-regulation of Fc receptor IIIA α (CD16-II) on NK cells induced by anti-CD16 MAb is independent of protein tyrosine kinases and protein kinase C. Cell Immunol., 158, 1994, 208-217.
6. BOURON, A., REBER, B.F.: Differential modulation of pharmacologically distinct components of Ca currents by protein kinase C activators and phosphatase inhibitors in nerve-growth-factor-differentiated pheochromocytoma (PC12) cells. Pflügers Arch., 427, 1994, 510-516.
7. BOUTIN, J.: Tyrosine protein kinase inhibitors and cancer. Int. J. Biochem., 26, 1994, 1203-1226.
8. BRUNO, S., ARDELT, B., SKIERSKI, S.J., TRAGANOS, F., DARZYNKIEWICZ, Z.: Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res., 52, 1992, 470-473.
9. CHAUDHARY, P.M., RONINSON, I.B.: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst., 85, 1993, 632-639.
10. CHAMBERS, T.C., ZHENG, B., KUO, J.F.: Regulation by phorbolester and protein kinase C inhibitors and by a protein phosphatase inhibitor (okadaic acid) of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant KB cells. Mol. Pharmacol., 41, 1992, 1008-1015.
11. CHORVÁTH, B., SEDLÁK, J., NOVOTNÝ, L.: The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line. Int. J. Cancer, 59, 1994, 852-853.
12. CORDGE, P.C., RYVES, W.J.: Inhibitors of protein kinase C. Cell. Signal., 6, 1994, 871-882.
13. COULDWELL, W.T., HINTON, D.R., HE, S., CHEN, T.C., SEBAT, I., WEISS, M.H., LAW, R.E.: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett., 23, 1994, 43-46.
14. CRISSMAN, H.A., GADBOIS, D.B., TOBEY, R.A., BRADBURY, E.M.: Transformed mammalian cells are deficient in kinase mediated control of progression through the G1 phase of their cell cycle. Proc. Natl. Acad. Sci. USA, 88, 1991, 7580-7584.
15. DARZYNKIEWICZ, Z.: Apoptosis in antitumor strategies: Modulation of cell cycle or differentiation. J. Cell. Biochem., 58, 1995, 151-159.
16. DURAJ, J., KOVÁČIKOVÁ, M., SEDLÁK, J., KOPPEL, J., SOBEL, A., CHORVÁTH, B.: The protein kinase C inhibitor H7 blocks phosphorylation of stathmin during TPA-induced growth inhibition of human pre-B leukemia REH6 cells. Leukemia Res., 19, 1994, 457-461.
17. EFFERTH, T., VOLM, M.: Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms. Cancer Lett., 70, 1993, 197-202.
18. FALCIERI, E., MARTELLI, A.M., BAREGGI, R., CATALDI, A., COCCO, L.: The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-4 cells without concomitant DNA fragmentation. Biochem. Biophys. Res. Commun., 28, 1993, 19-25.
19. FINDIK, D., SONG, Q., HIDAKA, H., LAVIN, M.: Protein kinase A inhibitors enhance radiation-induced apoptosis. J. Cell Biochem., 57, 1995, 12-21.
20. GEROSA, F., TOMMASI, M., BENATI, C., GANDINI, G., LIBONATI, M., TRIDENTE, G., CARRA, G., TRINCHIERI, G.: Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity induced by rIL-2, rIL-12 and rIFN-α in human NK cells. Cell Immunol., 150, 1993, 382-390.
21. GRANT, S., TURNER, A.J., BARTIMOLE, T.M., NELMS, P.A., JOE, V.C., JARVIS, W.D.: Modulation of 1-[β-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C. Oncol. Res., 6, 1994, 87-99.
22. GRANT, S., JARVIS, W.D., SWERDLOW, P.S., TURNER, A.J., TRAYLOR, R.S., WALLACE, J.H., LIN, P.S., PETTIT, G. R., GEWIRTZ, D.A.: Potentiation of the activity of 1[β-D-arabinofuranosyl] cytosine by the protein kinase C activator bryostatin 1: Association with enhanced fragmentation of mature DNA. Cancer Res., 52, 1992, 6270-6278.
23. GUPTA, S., PATEL, K., SINGH, H., GOLAPUDI, S.: Effect of calphostin C (PKC inhibitor) on daunorubicin resistance in P388/AR cells and HL60/AR cells: Reversal of drug resistance possibly via P-glycoprotein. Cancer Lett., 76, 1994, 139-145.
24. HAIMOWITZ-FRIEDMAN, A., BALABAN, N., MCLOUGHLIN, M., EHLEITER, D., MICHAELI, J., VLODAVSKY, I., FUKS, Z.: Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res., 54, 1994, 2591-2597.
25. HEIKKILA, J., JALAVA, A., ERIKSSON, K.: The selective protein kinase inhibitor GF 109203X inhibits phorbol ester-induced morphological and functional differentiation of SH-SY5Y human neuroblastoma cells. Biochem. Biophys. Res. Commun., 197, 1993, 1185-1193.
26. HENRY, G.L., MCCORMACK, S.J., THOMIS, D.C., SAMUEL, C. J.: Mechanism of interferon action, translational control and the RNA-dependent protein kinase (PKR): antagonists of PKR enhance the translational activity of mRNAs that include a 161 nucleotide region from reovirus s1 mRNA. J. Biol. Regul. Homeost Agents, 8, 1994, 15-24.
27. HONMA, Y., OKABE-KADO, J., HOZUMI, M., UEHARA, M., MIZUNO, S.: Induction of erythroid differentiation of K-562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res., 49, 1989, 331-334.
28. HONMA, Y., KASUKABE, T., HOZUMI, M., SHIBATA, K., OMURA, S.: Effects of herbimycin A derivatives on growth and differentiation of K-562 human leukemic cells. Anti-Cancer Res., 12, 1992, 189-192.
29. HONMA, Y., KASUKABE, T., HOZUMI, M., MAEKI, N., SAKURAI, M., SAKASHITA, S., TSURUOKA, N.: Induction of differentiation of human leukemia cells with structurally altered c-abl (bcr-abl) gene by herbimycin A, an inhibitor of tyrosine kinase activity. Leukemia, 6, 1992, 229-231.
30. HUNAKOVÁ, L., SEDLAK, J., CHORVÁTH, B.: Phorbol ester-induced modulation of cell surface antigens on U-937 cells in protein-free medium: Effects of protein kinase and calmodulin inhibitors. Neoplasma, 40, 1993, 141-146.
31. HUNÁKOVÁ, L., SEDLÁK, J., KLOBUŠICKÁ, M., DURAJ, J., CHORVÁTH, B.: Tyrosine kinase inhibitor-induced differentiation of K-562 cells: Alterations of cell cycle and cell surface phenotype. Cancer Lett., 81, 1994, 81-87.
32. HUNÁKOVÁ, L., SEDLAK, J., KLOBUŠICKÁ, M., CHORVÁTH, B.: Phorbol ester (TPA)-mduced differential modulation of cell surface antigens in hemopoietic pluripotential leukemia (K-562) cell line: Effects of protein kinase inhibitors with broad- and PKC selective inhibitory activity. Neoplasma, 42, 1995, 249-253.
33. ISONO, F., WIDMER, H.R., HEFTI, F., KNUSEL, B.: Epidermal growth factor induces PC12 cell differentiation in the presence of the protein kinase inhibitor K-252A. J. Neurochem., 63, 1994, 1235-1245.
34. JALAVA, A., AKERMAN, K., HEIKKILA, J.: Protein kinase inhibitor, staurosporine, induces a mature neuronal phenotype in SH-SYS5 human neuroblastoma cells trough alpha-, beta- and zeta- protein kinase C-independent pathway. J. Cell Physiol., 155, 1993, 301-312.
35. JARVIS, W.D., TURNER, A.J., POVIRK, L.F., TRAYLOR, R.S., GRANT, S.: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res., 54, 1994, 1707-1714.
36. KATAGIRI, K., HATTORI, S., NAKAMURA, S., YAMAMOTO, S., YOSHIDA, T., KATAGIRI, T.: Activation of ras and formation of GAP complex during TPA-induced monocytic differentiation of HL-60 cells. Blood, 84, 1994, 1780-1789.
37. KAWADA, M., TAWARA, J., TSUJI, T., HONMA, Y., HOZUMI, M., WANG, J.Y., UMEZAWA, K.: Inhibition of Abelson oncogene function by erbstatin analogues. Drugs Exp. Clin. Res., 19, 1993, 235-241.
38. KIKKAWA, U., NISHIZUKA, Y.: The role of protein kinase C in transmembrane signalling. Ann. Rev. Cell Biol., 2, 1986, 149-168.
39. KUMAR, A., HAQUE, J., LACOSTE, J., HISCOTT, J., WILLIAMS, B.R.: Double-stranded RNA-dependent protein kinase activates transcription factor NF-B by phosphorylating I-B. Proc. Natl. Acad. Sci: USA, 91, 1994, 6288-6292.
40. LAREDO, J., HUYNH, A., MULLER, C., JAFFREZOU, J.P., BAILLY, J.D., CASSAR, G., LAURENT, G., DEMUR, C.: Effect of protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood, 84, 1994, 229-237.
41. LEE, S.B., ESTEBAN, M.: The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis. Virology, 199, 1994, 491-496.
42. LING, V.: The role of P-glycoprotein in drug resistance. In: Accomplishments in Cancer Research. Eds: Fortner, J.G., Rhoads, J.E. Philadelphia, J.B. Lippincott 1990.
43. LIU, Y., BHALLA, K., HILL, C., PRIEST, D.G.: Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell lines. Biochem. Pharmacol., 15, 1994, 1265-1272.
44. LORD, J.M., BUNCE, C.M., BROWN, G.: The role of protein phosphorylation in the control of cell growth and differentiation. Br. J. Cancer, 58, 1988, 549-553.
45. LUCAS, M., SANCHEZ-MARGALET, V., SANZ, A., SOLANO, F.: Protein kinase C activation promotes cell survival in mature lymphocytes prone to apoptosis. Biochem. Pharmacol., 47, 1994, 667-672.
46. LUNDGREN, K., BEACH, D.: Cell cycle inhibitory protein kinases. In: Accomplishments in Cancer Research 1990. Eds: Fortner, J.G., Rhoads, J.E. Philadelphia, J.B. Lippincott 1990, 162-173.
47. MA, L., MARQUARDT, L., TAKEMOTO, L., CENTER, M.S.: Regulation by phorbol ester and protein kinase C inhibitors and by protein phosphatase inhibitor (okadaic acid) of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol. Pharmacol., 41, 1992, 1008-1015.
48. MAKASHIMA, M., HONMA, Y., HOZUMI, M., SAMPI, K., MOTOYOSHI, K., NAGATA, N., HATTORI, M.: Differentiation of human myeloblastic leukemia ML-1 cells into macrophages by staurosporine, an inhibitor of protein kinase activities. Exp. Hematol., 21, 1993, 839-845.
49. MARKOVITS, J., LARSEN, A.K., SEGAL-BENDIRDJIAN, E., FOSSE, P., SAUCIER, J.M., GAZIT, A., LEVITZKI, A., UMEZAWA, K., JACQUEMIN-SABLON, A.: Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. Biochem. Pharmacol., 48, 1994, 549-560.
50. MAY, W.S., TYLER, P.G., ITO, T., ARMSTRONG, D.K., QATSHA, K.A., DAVIDSON, N.E.: Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of bcl-2 alpha in association with suppression of apoptosis. J. Biol. Chem., 269, 1994, 26 865-26 870.
51. MCCONKEY, D.J., HARTZELL, P., JONDAL, M., ARRENIUS, S.: Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase. C. J. Biol. Chem., 264, 1989, 13 399-13 402.
52. MEYER, T., REGENASS, U., FABBRO, D., ALTERI, E., ROSSEL, J., MULLER, M., CARAVATTI, G., MATTER, A.: A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int. J. Cancer, 43, 1989, 851-856.
53. NISHIZUKA, Y.: Studies and prospectives of the protein kinase C family for cellular regulation. In: Accomplishments in Cancer Research. Eds: Fortner, J.G., Rhoads, J.E. Philadelphia, J.B. Lippincott, 1988, 100-120.
54. PAGLIACCI, M.C., SMACCHIA, M., MIGLIORATI, G., GRIGNANI, F., RICCARDI, C., NICOLETTI, I.: Growth-inhibitory effects of the natural phytoestrogen genistein in MCF-7 human breast cancer cells. Eur. J. Cancer, 30A, 1994, 1675-1682.
55. PONGRACZ, J., TUFFLEY, W., JOHNSON, G.D., DEACON, E.M., BURNETT, D., STOCKLEY, R.A., LORD, J.M.: Changes in protein kinase C isoenzyme expression associated with apoptosis in U937 myelomonocytic cells. Exptl. Cell Res., 218, 1995, 430-438.
56. RINAUDO, M.S., SU, K., FALK, L.A., HALDER, S., MUFSON, A.D.: Human interleukin-3 receptor modulated bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood, 86, 1995, 80-88.
57. SEDLÁK, J., HUNÁKOVÁ, L., DURAJ, J., CHORVÁTH, B., NOVOTNÝ, L.: Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anti-Cancer Drugs, 6, 1995, 70-76.
58. SEDLÁK, J., ŠULIKOVÁ, M., HUNÁKOVÁ, L., CHORVÁTH, B.: Differential effects of protein kinase inhibitors (staurosporine and CGP 41 251) on TPA-induced homotypic aggregation and cell surface adhesion antigen expression in human monoblastoid cell line U-937. Neoplasma, 42, 1995, 159-165.
59. SEGAL-BENDIRDJIAN, E., JACQUEMIN-SABLON, A.: Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp. Cell Res., 218, 1995, 201-212.
60. SHAPIRA, L., TAKASHIBA, S., CHAMPAGNE, C., AMAR, S., VAN DYKE, T.E.: Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-α and IL-1β production by human monocytes. J. Immunol., 153, 1994, 1818-1824.
61. SPINOZZI, F., PAGLIACCI, M.C., MIGLIORATI, G., MORACA, R., GRIGNANI, F., RICCARDI, C., NICOLETTI, I.: The natural tyrosine kinase inhibitor, genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res., 18, 1994, 431-439.
62. TRAGANOS, F., GONG, J., ARDELT, B., DARZYNKIEWICZ, Z.: Effect of staurosporine on MOLT-4 cell progression through G2 and on cytokinesis. J. Cell Physiol., 158, 1994, 535-544.
63. UCKUN, F.M., TUEL-AHLGREN, L., SONG, C.W., WADDICK, K., MYERS, D.E., KIRIHARA, J., LEDBETTER, J.A., SCHIEVEN, G.L.: Ionizing radiation stimulates unidentified tyrosine-specific protein kinases in human B-lymphocyte precursors, triggering apoptosis and clonogenic cell death. Proc. Natl. Acad Sci. USA, 89, 1992, 9005-9009.
64. UCKUN, F.M., EVANS, W.E., FORSYTH, C.J., WADDICK, K.G., AHLGREN, L.T., CHELSTROM, L.M., BURKHARDT, A., BOLEN, J., MEYERS, D.E.: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science, 267, 1995, 886-891.
65. UTZ, I., HOFER, S., REGENASS, U., HILBE, W., THALER, J., GRUNICKE, H., HOFMANN, J.: The protein kinase C inhibitor CGP 41 251, a staurosporine derivative with antitumor activity reverses multidrug resistance. Int. J. Cancer, 57, 1994, 104-110.
66. VAN DER BRUGGEN, T., KOK, P.T.M., BLOM, M., VERHOEEVEN, A.J., RAAIJMAKERS, J.A.M., LAMMERS, J.W.J., KOENDERMAN, L.: Transient exposure of human eosinophils to the protein kinase C inhibitors CGP39-360, CGP41-251 and CGP44-800 leads to priming of the respiratory burst induced by opsonized particles. J. Leukocyte Biol., 54, 1993, 552-557.
67. VERSANTVOORT, C.H.M., SCHUURHUIS, G.J., PINEDO, H.M., EEKMAN, C.A., KUIPER, C.M., LANKELMA, J., BROXTERMAN, H.J.: Genistein modulates the decreased drug accumulation in non-P glycoprotein mediated multidrug resistant tumor cells. Br. J. Cancer, 68, 1993, 939-946.
68. WATANABE, T., KONDO, K., OISHI, M.: Induction of in vitro differentiation of mouse erythroleukemia cells by genistein, an inhibitor of protein tyrosine kinase. Cancer Res., 51, 1991, 764-768.
69. YEN, A., SOONG, S., KWON, H.J., YOSHIDA, M., BEPPU, T., VARVAYANNIS, S.: Enhanced cell differentiation when Rb is hypophosphorylated and down-regulated by radicicol, a src-kinase inhibitor. Exp. Cell Res., 214, 1994, 163-171.
70. ZHENG, B., CHAMBERS, T.C., RAYNOR, R.L., MARKHAM, P.N., GEBEL, H.M., VOGLER, W.R., KUO, J.F.: Human leukemia K-562 cell mutant (K-562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase C epsilon, exhibits multidrug phenotype and expresses drug pump P-glycoprotein. J. Biol. Chem., 269, 1994, 12 332-12 338.
71. ZIMMERMANN, A., KELLER, H.: Effects of staurosporine, K-252a and other structurally related protein kinase inhibitors on shape and locomotion of Walker carcinosarcoma cells. Br. J. Cancer, 66, 1992, 1077-1082.